Medtronic plc (MDT)
NYSE: MDT · Real-Time Price · USD
84.22
+1.32 (1.59%)
At close: Apr 14, 2025, 4:00 PM
83.76
-0.46 (-0.55%)
Pre-market: Apr 15, 2025, 7:51 AM EDT
Medtronic Revenue
Medtronic had revenue of $8.29B in the quarter ending January 24, 2025, with 2.51% growth. This brings the company's revenue in the last twelve months to $33.20B, up 2.72% year-over-year. In the fiscal year ending April 26, 2024, Medtronic had annual revenue of $32.36B with 3.64% growth.
Revenue (ttm)
$33.20B
Revenue Growth
+2.72%
P/S Ratio
3.29
Revenue / Employee
$349,463
Employees
95,000
Market Cap
108.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 26, 2024 | 32.36B | 1.14B | 3.64% |
| Apr 28, 2023 | 31.23B | -459.00M | -1.45% |
| Apr 29, 2022 | 31.69B | 1.57B | 5.21% |
| Apr 30, 2021 | 30.12B | 1.20B | 4.16% |
| Apr 24, 2020 | 28.91B | -1.64B | -5.38% |
| Apr 26, 2019 | Pro | Pro | Pro |
| Apr 27, 2018 | Pro | Pro | Pro |
| Apr 28, 2017 | Pro | Pro | Pro |
| Apr 29, 2016 | Pro | Pro | Pro |
| Apr 24, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MDT News
- 7 days ago - The Best Large-Cap Stocks to Buy - Kiplinger
- 14 days ago - Best Dividend Aristocrats For April 2025 - Seeking Alpha
- 15 days ago - Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients - PRNewsWire
- 26 days ago - Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy - Seeking Alpha
- 27 days ago - FDA classifies recall of Medtronic embolization devices as 'most serious' - Reuters
- 27 days ago - Dividend Kings Of The Future - Seeking Alpha
- 5 weeks ago - CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay Platform - GlobeNewsWire
- 5 weeks ago - SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients - PRNewsWire